Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer
Idorsia Pharmaceuticals Ltd. / Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.
Lesen Sie auch
-
As Chief Commercial Officer Simon Jose will join the Idorsia Executive Committee
Allschwil, Switzerland - October 23, 2018
Idorsia Ltd (SIX: IDIA) today announced that Simon Jose will join the company as Chief Commercial Officer on December 1, 2018. Mr. Jose will also be a member of the Idorsia Executive Committee.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Idorsia commented:
"I am very pleased and honored that Simon Jose has joined the team at Idorsia. Simon will be key to realizing the full potential of our assets and making strategic decisions on how to commercialize
them. Simon brings a wealth of experience and broad expertise covering the General Practitioner market as well as specialty care. He also brings the necessary understanding of the US environment. I
look forward to working with Simon as he creates and builds our commercial organization to deliver our innovative therapies to patients."
Simon Jose commented:
"I was attracted to Idorsia by the quality and breadth of the pipeline. It has great potential across a number of different medical settings, which from a commercial perspective, is incredibly
exciting and challenging. As I have learned more about Idorsia and the people working there, it is clear that the pipeline is borne from a focus on quality science and a commitment to patients, two
attributes which personally drive me. I have been struck by the enthusiasm and passion I have experienced at Idorsia and relish the opportunity to build a successful commercial organization from
the ground up."
About Simon Jose
Simon Jose is a British national with over 30 years of experience in the pharmaceutical industry, including 7 years in the US. In that
time, he has held various commercial roles of growing responsibility, gaining experience in sales, managing and launching multi-billion dollar products, developing global strategies, and working
with R&D to develop competitive pipelines. In 2008, Simon was appointed as General Manager of GSK's home market in the UK. In 2012, Simon was appointed President of Stiefel, a global specialty
dermatology company recently acquired by GSK. In this role Simon led the Global Executive Team, managing an organization of 3'000 people, through a period of significant change. From 2015 and
immediately prior to Idorsia, Simon was the Senior Vice President, Head Global Franchises & Platforms at GSK where he led combined commercial and medical teams for Respiratory,
Immuno-Inflammation, Oncology, and Infectious Diseases.